🇺🇸 FDA
Patent

US 11649251

Substituted inhibitors of menin-MLL and methods of use

granted A61KA61K31/5355A61K45/06

Quick answer

US patent 11649251 (Substituted inhibitors of menin-MLL and methods of use) held by Kura Oncology, Inc. expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Kura Oncology, Inc.
Grant date
Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/5355, A61K45/06, A61K9/0019, A61K9/0053